IE54350B1 - Tropyl and pseudotropyl alkyl-benzoates and their use in migraine treatment - Google Patents

Description

The invention relates to the treatment of migraine with certain tropyl and pseudotropyl alkylbenzoates and provides pharmaceutical compositions comprising said compounds. Further, the invention also provides said compounds for use in treating migraine and, when said compounds are novel, it provides said novel compounds per se.

Acute attacks of migraine are usually treated with a peripheral vasoconstrictor, such as ergotamine, which may be co-administered with caffeine, and dihydroergotamine; an antipyretic analgesic, such as acetylsalicylic acid or p-acetylaminophenol; and/or an anti-emetic such as cyclizine, metoclopramide and thiethylperazine. It has also been reported (J.B.

Hughes; Med. J. Aust. 2, No. 17, 580, 1977) that immediate relief of acute migraine attack can be obtained by slow intravenous injection of metoclopramide (10 mg) .

It is believed that 5-hydroxytryptamine (5-HT) is the naturally occurring substance most likely to play a role in the pathophysiology of migraine. Increased amounts of 5-HT and its metabolite 5-hydroxyindoloacetic acid are excreted in the urine during most attacks. Further, plasma and platelet 5-HT concentrations fall rapidly at the onset of an attack and remain low whilst the headache persists.

Moreover, attacks of migraine have been clearly associated with periods of thrombocytopaenia in certain patients. It has been proposed that compounds which block the activity of 5-HT would be of use in the treatment of migraine (J.R. Fozard, International Headache Congress 1980) reported in Advances in Neurology, Vol 33, Haven Press, New York 1982).

The known migraine prophylactic drugs methysergide, propranolol, amitriptyline, and chlorpromazine have widely different pharmacological activities but are all 5-HT D-receptor antagonists at the doses used clinically for the treatment of migraine. Metoclopramide is a potent 5-HT M-receptor antagonist and it has been proposed (J.R. Fozard supra) that, blockade of the M-receptor present on afferent sensory neurones affords symptomatic relief in an acute migraine attack.

The potency as 5-HT M-receptor antagonists of (-) cocaine and some related compounds, including benzoyl pseudotropine (i.e. pseudotropyl benzoate) and benzoyl tropine (i.e. tropyl benzoate), has been reported (J.R. Fozard et al, Eur. J. Pharmacol., 59(1979), 195-210) but, with the exceptions of nor(-)cocaine and benzoyl tropine, none are as potent as metoclopramide. The pA2 values reported for nor(-)cocaine, benzoyl tropine, and benzoyl pseudotropine are 7.7, 7.2 and 7.0 respectively whilst the pA2 5-HT value determined for metoclopramide by the same procedure is 7.2 (J.R. Fozard et al. Eur. J. Pharmacol., 49(1978), 109-112).

It has been reported in Patent Specification ITq5 4 2 5 8t6at substitution of tropyl benzoate with alkyl, alkoxy or halogen in the 3, or 3 and 5, or 3, 4 and 5 positions of the benzene ring surprisingly enhances its potency as a 5-HT M-receptor antagonist. Tests conducted with tropyl-4-chlorobenzoate (pA2 7.0), tropyl-4-methylbenzoate (pA2 7.8), tropyl-3,4-dichlorobenzoate (pA2 7.8) and tropyl-3,4-dimethoxybenzoate (pA2 7.2), indicated that corresponding substitutions elsewhere in the benzene ring would not provide the same order of increase in potency. Further, tests conducted with pseudotropyl-3,5-dimethoxybenzoate (pA2 6.6), and pseudotropyl-3,4,5-trimethoxybenzoate (pA2 5.7) indicated that corresponding substitutions in the benzene ring of pseudotropyl benzoate actually would reduce its potency as a 5-HT M-receptor antagonist. However, it has now surprisingly been found that substitution by alkyl in at Least the 2 position or in the 3,4 position of the benzene ring of tropyl benzoate and pseudotropyl benzoate and in the 3, 3 and 5, or 3, 4 and 5 positions of the benzene ring of pseudotropyl benzoate does substantially enhance potency as a 5-HT M-receptor antagonist.

All the tropyl benzoate derivatives of Formula I except tropy1-2-methylbenzoate, and all the pseudotropyl benzoates of Formula 1 are believed to be novel compounds. Tropyl-2-methylbenzoate is discloo·,.. in Al-Yahya et al (J. Chem. Soc. Perkins Trans. 1, 1979 (9), 2130-2) but no pharmacological use has been reported for the compound.

According to a first aspect of the invention, 15 there are provided pharmaceutical compositions, for use in the treatment of migraine and other vascular headaches, containing a tropyl or pseudotropyl benzoate derivative of the following general Formula I:H..C-CH-CH„ I ί fiCH., CH - 0„C-Ar I I „2C -CH -Cll2 wherein :Ar represents n represents 0 or an integer from 1 to 3; Rl represents C1-C4 alkyl; R2 represents C1-C4 alkyl, halogen or C1-C4 alkoxy, provided that R2 is the same as Rl when ri is 2 or 3; and R3 and R4 independently represent hydrogen, C1-C4 alkyl, C1-C4 alkoxy or halogen provided that for tropyl derivatives R3 is alkyl and R4 is hydrogen, or a pharmaceutically acceptable salt thereof.

The pharmaceutical compositions of the invention axe provided in unit dose form for the effective relief of migraine comprising a compound of general Formula I in admixture or otherwise associated with a pharmaceutically acceptable diluent or carrier and containing 0.5 to 100 mg per unit dose. Usually, said compositions will contain 1 to 50 mg, especially 3 to 30 mg, per unit dose.

According to a second aspect of the invention, there are provided per se all compounds of Formula X except tropyl-2-methylbenzoate.

Migraine is treated by administering to a patient suffering migraine, an effective migraine relieving amount of a compound of Formula I. Said amount usually will be in —7 the range 0.01 mg/kg to 10 mg/kg, especially 0.03 mg/kg to 3.0 mg/kg. It is also contemplated that the compounds of Formula I can be used in the prophylaxis of migraine by administering to a patient at risk of migraine an effective migraine-prophylatic amount of the compound.

When the bicylic ring of a compound of Formula I is in the endo configuration, the compound is a tropyl benzoate and, when it is in the exo configuration, the compound is a pseudotropyl benzoate. Presently, the tropyl benzoates are preferred over the pseudotropyl benzoates.

The compounds of general Formula I have the benzoyloxy moiety substituted by C4-C4 alkyl in at least the 2 or 3 position and optionally in other positions. In particular R4 represents C4-C4 alkyl; R2 represents C1-C4 alkyl, C1-C4 alkoxy or halogen but is the same as R4 when there are two or three Rg substituents; R3 can represent C1~C4 alkyl, C4-C4 alkoxy or halogen instead of hydrogen; R4 can represent 0^-64 alkyl., C1-C4 alkoxy or halogen instead of hydrogen; and ti is 0 or an integer up to 3 preferably 0, 1 or 2. The tropyl benzoates (but not pseudotropyl benzoates) of Formula I substituted at the 3-position alone, the 3 and 5 positions only, or the 3,4 and 5 positions only are excluded because they are already the subject ι the previously acknowledged co-pending application In general Formula I, Ar can represent phenyl substituted as shown in the following Table I:- 05 TABLE I Position 2 3 4 5 6R1 H H H H Bl b2 H H H Kl H «2 H H Bl H 11 K2 H 10 «1 H H H K2 Bl Bl Bl H 11 «I Bl H Kl H Bl Bl H ttR1 15 Bl HR1R1 H Bl H «1 HR1 Bl Bl Kl Bl H Bl Bl «I H Kl 20 Bl Bl ttR1 Kl * H Bl H H H II Bl b3 H 11 * 11 Bl Hr4 H 25 * H Bl b3 r4 H * pseudotropyl benzoate only In the table above Ηχ, R2, 83 and R4 are as defined in connection with Formula I except that neither R3 nor R4 represents hydrogen.

Examples of C4-C4 alkyl groups which are 05 represented by R4 and can be represented by R2, R3 and R4 are methyl, ethyl, n-propyl, n-butyl and iso-propyl with methyl and ethyl being preferred.

Examples of C4-C4 alkoxy groups which can be represented by R2, R3 and R4 are methoxy, ethoxy, n-propoxy, n-butoxy and iso-propoxy, with ethoxy and especially, methoxy being preferred.

The halogens which can be represented by R2, R3 and R4 are bromine, chlorine, fluorine and iodine with bromine, fluorine and, especially, chlorine being preferred.

One preferred class of compounds of Formula I are those pseudotropyl benzoates and tropyl benzoates in which Ar represents:20 wherein n is 0 or an integer from 1 to 3, R4 represents C1-C4 alkyl, and R2' represents C1-C4 alkyl or chlorine provided that R2' is the same as K4 when n is 2 or 3.

Another preferred class of compounds of the invention are those pseudotropyl benzoates and tropyl benzoates of Formula I in which Ar represents:- wherein Ry and Rg' independently represent CX-C4 alkyl.

Yet. another preferred class of compounds are 10 those pseudotropyl benzoates of Formula 1 in which Ar represents:- wherein R| represents C1-C4 alkyl and Rg' and R41 independently represent hydrogen or C1-C4 alkyl.

In a presently particularly preferred embodiment of the invention, the compositions contain those pseudotropyl benzoates and, preferably, tropyl benzoates of Formula I in which Ar presents phenyl substituted only by C1-C4 alkyl, especially methyl, at the 2; 2, 3; 2, 4; 2, 5; or 3, 4 positions. The said especially preferred methyl-substituted compounds are the following:tropyl-2-methylbenzoate, tropyl-2,3-dimethylbenzoate, OS tropyl-2,4-dimethylbenzoate, tropyl-2,5-dimethylbenzoate, tropyl-3,4-dimethylbenzoate, pseudotropyl-2-methylbenzoate, pseudotropyl-2,3-dimethylbenzoate, pseudotropyl-2,4-dimethylbenzoate, pseudotropyl-2,5-dimethylbenzoate, pseudotropyl-3,4-dimethylbenzoate.

In another presently especially preferred embodiment of the invention, the compounds are those pseudotropyl benzoates of formula I in which Ar represents phenyl substituted only by (^-04 alkyl, especially methyl, at the 3; 3, 5; or 3, 4, 5 positions. The said especially preferred methyl-substituted compounds are the following:20 pseudotropyl-3-methylbenzoate, pseudotropyl-3,5-dimethylbenzoate, pseudotropyl-3,4,5-dimethylbenzoate.

In addition to the preferred compounds specified above, the following are illustrative compounds of Formula I:12 '5 ** rj ft V tropyl 2-methyl-3-chlorobenzoate; tropyl 2-methyl-4-chlorobenzoate; tropyl 2-methyl-5-chlorobenzoate; tropyl 2,3,5-trimethylbenzoate; tropyl 2,3,4,5-tetramethylbenzoate; tropyl 2-ethylbenzoate; tropyl 3,4-diethylbenzoate; tropyl 2-methy1-4-methoxybenzoate; pseudotropyl 2,3,5-trimethylbenzoate; pseudotropyl 2-methy 1-4-eh.lorobenzoate; The compounds of Formula I block the M-receptors for 5-hydroxytryptamine (5-HT) on afferent sensory neurones, certain of which subserve the transmission of pain. As explained above, the blocking of such M-receptors is believed to be a mechanism by which the symptoms of migraine can be relieved.

Accordingly, the compounds of Formula I are useful in the treatment of migraine when administered in amounts sufficient to effectively block the said M-receptors.

The activity of the compounds against 5-HT can be assessed by determining their pAg values in the isolated rabbit heart as described by Fozard et at Europ. J. Pharmacol. 59, 195-210 (1979). In the method described the molar concentration of antagonist which reduces the effects of twice the ED50 of 5-HT to that of the ED50 in the absence of antagonist is determined. The pA3 value is the negative logarithm of said molar concentrations. In general terms, the higher the pA2 value the more potent is the compound.

The pA2 values of some representative compounds 05 of Formula I are given in the following TABLE II Table II:- Compound ΕΔ2_5ςΗΪ tropyl 2-methylbenzoate 8.1. tropyl 3,4-dimethylbenzoate 8.2 10 tropyl 2,5-dimethylbenzoate 8.6 tropyl 2,4-dimethylbenzoate 8.8 pseudotropyl 3,5-dimethylbenzoate 8.9 The pA2 values of some related compounds to those of the invention are given in the following 15 Table III for comparative purposes. TABLE III Compound pA9 5-HT pseudotropyl-3,4,5-trimethoxybenzoate 5.7 pseudotropyl-3,5-dimethoxybenzoate 6.6 20 pseudotropyl-4-chlorobenzoate 6.7 pseudotropyl benzoate 7.0 tropyl 4-chlorobenzoate 7.0 tropyl 3,4-dimethoxybenzoate 7.2 tropyl benzoate 7.2 25 pseudotropyl-3,4-dichlorobenzoate 7.5 tropyl 4-methylbenzoate 7.8 tropyl 3-methylbenzoate 8.1 tropyl 3,5-dime thoxybenzoate 8.4 tropyl 3,4,5-trimethoxybenzoate 8.5 tropyl 3-chlorobenzoate 8.8 tropyl 3,5-dimethylbenzoate 9.0 tropyl 3,5-dichlorobenzoate 9.3 It will be noted inter alia from Tables IX and III that the compounds of Formula I show in this test a potency as 5-RT M-receptor antagonists at least an order greater than that of tropylbenzoate or pseudo10 tropyl benzoate.

The activity of the compounds against 5-HT can be assessed in vivo by measurement of the effect of the compound on the Von Bezold-Jarisch Reflex induced by 5-HT injected intravenously into the rat (see Paintal A.S., Physiol. Rev. 53 159-227, 1973). The transient cardiac slowing arises from an increased efferent vagus activity arising from stimulation by 5-HT of sensory afferent fibres in and around the heart.

The compounds of Formula I are believed to be highly selective in their action against 5-HT M-receptor. Their potency against other 5-HT receptors and other spasmogens, in particular oxytocin, acetylcholine, histamine and calcium, is believed to be at least two orders lower than that against 5-HT M-receptors.

Accordingly, their use in the treatment of migraineshould be without any side effects.

The compounds of Formula 1 can be administered in various manners to achieve the desired effect. The compounds can be administered alone or in the form of pharmaceutical preparations to the patient being treated either orally or parenterally, for example, subcutaneously or intravenously. The amount of compound administered will vary and can be any effective migraine-relieving amount. Depending upon the patient and the mode of administration, the quantity of compound administered may vary over a wide range to provide from about 0.01 mg/kg to 10 mg/kg, usually 0.03 to 3.0 mg/kg, of body weight of the patient per dose. Unit doses of these compounds can contain, for example, from about 0.5 mg to 100 mg, usually 1 to 50 mg and preferably 3 to 30 mg, of the compound and may be administered, for example, from 1 to 4 times daily.

The term unit dosage form is used herein to mean a single or multiple dose form containing a quantity of the active ingredient in admixture with or otherwise in association with ttie diluent or carrier, said quantity being such that one or more predetermined units are normally required for a single therapeutic administration. In the case of multiple dose forms such as liquids or scored tablets, said predetermined unit will be one fraction, such as a 5 ml (teaspoon) quantity of a liquid or a half or quarter of a scored tablet, of the multiple dose form.

In the composition aspect of the invention there 05 are provided pharmaceutical formulations in which form the active compounds of the invention will normally be utilized. Such formulations are prepared in a manner well known per se in the pharmaceutical art and usually comprise at least one active compound of the invention in admixture or otherwise in association with a pharmaceutically acceptable carrier or diluent therefor. For making those formulations the active ingredient will usually be mixed with a carrier, or diluted by a diluent, or enclosed or encapsulated in a capsule, sachet, cachet, paper or other container. A carrier or diluent may be solid, semi-solid or liquid material which serves as a vehicle, excipient or medium for the active ingredient. Suitable carriers or diluents are well known per se.

The formulations of the invention may be adapted for enteral or parenteral use and may be administered to the patient in the form of, e.g. tablets, capsules, suppositories, solutions, or suspensions.

In the specific examples included hereinbelow illustrative examples of suitable pharmaceutical formulations are described.

The derivatives of Formula I can be used in migraine therapy with antimigraine drugs having different inodes of action. Such drugs include those used prophylactically, such as barbiturates, diazepam, chlorpromazine, amitriptyline, propranolol, methysergide, pizotifen, cyproheptadine, dihydroergotamine, and clonidine, and those used in the acute attack, such as vasoconstrictor agents, e.g. ergotamine and dihydroergotamine, analgaesic/ antiinflammatory agents, e.g. aspirin, paracetamol and indomethacin, or anti-nauseants, e.g. cyclizine, metoclopramide, and triethylperazine (see Fozard, J.R. J. Pharm. Pharmacol. 27, 297-321 (1975); Saper, J.R., J. Amer. Med. Assoc. 239, 480-484 (1978); Fozard, J.R., supra.) As an example, compounds of general Formula 1 would be beneficial in combination with aspirin 300-1200 mg or methysergide, 2-6 mg given daily.

The compounds of general Formula I can be prepared in manner known per se from tropine or pseudotropine and an acid halide of the following general Formula IV:XOC-Ar Formula IV wherein Ar is as defined in connection with Formula I, and X represents halogen, especially chlorine.

When preparing tropyl benzoate derivatives, the reaction usually will be carried out in the absence of a solvent by heating, at for example a temperature in the range 140' to lb'O'C, the acid halide with a hydrohalide salt of tropine whilst stirring. Hydrogen halide is evolved and the mixture first becomes liquid but subsequently becomes solid. Heating is continued for about 15 mins after solidification and the mixture is then cooled and added to water. The product is the hydrohalide of the compound of Formula I and the free base can be obtained by addition of aqueous base, such as sodium or potassium, carbonate, which does not hydrolyse the ester, to render the aqueous product solution alkaline and subsequent extraction of the free base with a suitable organic solvent such as, for example, diethylether, ethylacetate and methylene· chloride. The organic solution is subsequently evaporated and the residue recrystallized from, for example, aqueous methanol.

When preparing pseudotropyl benzoate derivatives, the reaction usually will be carried out by stirring the acid halide and pseudotropine in an aprotic solvent, preferably methylene chloride or acetonitrile, at ambient temperature. The solvent is evaporated off, usually under reduced pressure, after S4350 about 2 to 16 hours and water added to the residue, followed by aqueous base, such as sodium or potassium carbonate, which does not hydrolyse the ester, to render the aqueous product solution alkaline. Subsequently desired free base is extracted with a suitable organic solvent such as, for example, diethyl ether, ethylacetate and methylene chloride.

The organic solution is then washed with water to remove excess pseudotropine and dried. The organic solvent is evaporated off and the free base recrystallized from, for example, aqueous methanol. Alternatively, the crude free base can be converted into an acid addition salt, preferably hydrochloride, by addition of an ethereal solution of the acid. The acid salt is recrystallized from, for example ethanol or isopropanol.

As mentioned previously, the compounds of Formula 1 can be used in the form of their pharmaceutically acceptable acid addition salts.

The pharmaceutically acceptable acid addition salts can be non-toxic addition salts with suitable acids, such as those with inorganic acids, for example hydrochloric, hydrobromic, nitric, sulfuric or phosphoric acids, or with organic acids, such as organic carboxylic acids, for example, glycollic, maleic, hydroxymaleic, malic, tartaric, citric, a 4 3 5 v salicylic, o-acetyloxybenzoic, nicotinic or isonicotinic, or organic sulphonic acids, for example methane sulphonic, ethane sulphonic, 2-hydroxyethane sulphonic, toluene-p-sulphonic, or naphthalene-205 sulphonic acids.

Apart from pharmaceutically acceptable acid addition salts, other acid addition salts, such as for example, those with picric or oxalic acid, may be serve as intermediates in the purification of the compounds or in the preparation of other, for example, pharmaceutically acceptable, acid addition salts, or are useful for identification or characterisation of the bases.

An acid addition salt may be converted into the 15 free compound according to known methods, for example, by treating it with a base, such as with a metal hydroxide or alkoxide, for example an alkali or alkaline earth metal hydroxide, for example, lithium hydroxide, sodium hydroxide, potassium hydroxide or calcium hydroxide; with a metal carbonate, such as an alkali metal or an alkaline earth metal carbonate or hydrogen carbonate, for example, sodium, potassium or calcium carbonate or hydrogen carbonate; with trialkylamine; or with an anion exchange resin.

An acid addition salt may also be converted into another acid addition salt according to known methods; 4 3 5 0 for example, a salt with an inorganic acid may be treated with a metaL salt, tor example a sodium, barium or silver salt, or an acid in a suitable diluent, in which a resulting inorganic salt is insoluble and is thus removed from the reaction medium. Acid addition salt may also be converted into another acid addition salt by treatment with an anion exchange preparation.

The invention is illustrated in the following non-limiting Examples.

EXAMPLE 1 TROPYL-3,4-DIMETHYLBENZOATE (i.e. 3,4-DIMETHYLBENZOIC ACID END0-8-METHYL-8-AZABlCYCL0[3,2,1]0CT-3-YL ESTER (FORMULA I, ENDO, Ar= 3,4-dimethyIphenyl) A stirred mixture of tropine hydrochloride (1.76 g) and 3,4-dimethyl benzoyl chloride (1.65 g) is heated at 130-140C for 30 minutes during which time the mixture liquifies, evolves hydrogen chloride gas and resolidifies. A solution of the cooled solid in water is basified with a solution of potassium carbonate and the base extracted with ethyl acetate. The ethyl acetate solution is washed several times with water, dried over magnesium sulphate, and evaporated to give the free base which is converted to the hydrochloride by the addition of ethereal hydrogen chloride. Recrystallization of the precipitated solid d 3 S Is from ethanol gives crystals of tropyl 3,4-dimethy1benzoate hydrochloride mp. 270-271’C.

The following compounds are prepared by the same method: 05 tropyl 2-methylbenzoate hydrochloride m.p. 262-3'C; tropyl 2,4-dimethylbenzoate hydrochloride m.p. 256’C; tropyl 2,5-dimethylbenzoate hydrochloride m.p. 269.5-270’C.

EXAMPLE 2 PSEUDOTROPYL 3,5-DIMETHYLBENZOATE (i.e. 3,5-D1METHYL-BENZ0IC ACID EX0-8-METHYL-8-AZABICYCL0[3,2,l]0CT-3-YL ESTER) (FORMULA I, EXO, Ar = 3,5-dimethylphenyl) Pseudotropine (1.41 g) and 3,5 dimethylbenzoylchloride (1.65 g) in methylene chloride (50 ml) is stirred at ambient temperature for 3 hours. The solvent is evaporated off under reduced pressure and the residue treated with water (50 ml) and saturated aqueous potassium carbonate solution (5 ml) is added. The liberated oil is extracted into diethylether, the ethereal solution washed several times with water and then dried over anhydrous magnesium sulfate.

Distillation of the dried ethereal solution gives a residue which is treated with anhydrous diethyl ether 4 3 5 Ο and ethereal hydrogen chloride. Crystallization of the precipitate from ethanol affords pseudotropy1-3,5dimethylbenzoate hydrochloride mp 245C.

Xn the following Examples relating to pharmaceutical compositions, the term active compound is used to indicate the compound tropyl-2,4-dimethylbenzoate. This compound may be replaced in these compositions by any other compound of Formula I, for example by pseudotropyl-3,5-dimethylbenzoate. Adjustments in the amount of medicament may be necessary or desirable depending upon the degree of activity of the medicament as is well known in the art.

EXAMPLE 3 An illustrative composition for hard gelatin capsules is as follows:- (a) active compound 5 mg (b) talc 5 mg (c) lactose 90 mg The formulation is prepared by passing powders of (a) and (b) through a fine mesh screen and mixing them well. The powder is then filled into hard gelatin capsules at a net fill of 100 mg per capsule. «ί ·Λ 3 «2 if EXAMPLE 4 An illustrative composition for tablets is as follows:05 (a) active compound 5 mg (b) starch 43 mg (c) lactose 50 mg (d) magnesium stearate 2 mg The granulation obtained upon mixing the lactose with the compound (a) and part of the starch and granulating with starch paste is dried, screened, and mixed with the magnesium stearate. The mixture is compressed into tables weighing 100 mg each.

EXAMPLE 5 An illustrative composition for an injectable 15 suspension is the following 1 ml ampule for an intramuscular injection:Weight per cent (a) active compound 0.01 (b) polyvinylpyrrolidone 0.5 (c) lecithin 0.25 (d) water for injection to make 100.0 The material (a) - (d) are mixed, homogenized, and filled into 1 ml ampules which are sealed and autoclaved 20 minutes at 121’C. Each ampule contains 1.0 mg per ml of compound (a).

EXAMPLE 6 mg/suppository Active Compound 5 Oil of Theobroma (cocoa butter) 995 The medicament is powdered and passed through a B.S. No. 100 Sieve and triturated with molten oil of theobroma at 45'C to form a smooth suspension. The mixture is well stirred and poured into moulds each of nominal 1G capacity, to produce suppositories.

Claims (50)

1. A pharmaceutical composition in unit dose form for the treatment of migraine comprising, in admixture or otherwise? associated with a pharmaceutically 05 acceptable diluent or carrier, an amount ol' 0.5 to 100 mg per unit dose of a tropyl or pseudotropyl benzoate derivative of the following general Formula I:H,.C- CH- CH„ I 1 1 NCH„ CH - 0„C-Ar ’ll 2 H^C - CH- CK 2 10 wherein :- n represents 0 or an integer from 1 to 3 R 3 represents ¢4-04 alkyl; 45 R2 represents Cy-C^ alkyl, C4-C4 alkoxy or halogen provided that R2 is the same as R4 when n is 2 or 3; and R3 and R4 independently represent hydrogen, C4-C4 alkyl, C4-C4 alkoxy, or halogen provided 20 that for tropyl derivatives R 3 is alkyl and R4 is hydrogen; or a pharmaceutically acceptable salt thereof.

2. A composition as claimed in Claim 1 containing 1 to 50 mg of said compound per unit dose.

3. A composition as claimed in Claim 2 pontaining 3 to 30 mg of said compound per unit dose> 05

4. A composition as claimed in any one of the preceding claims wherein R^ represents methyl, R2 represents methyl, methoxy or chlorine, and R3 and R4 independently represent hydrogen, methyl, methoxy or chlorine, subject to the provisos set forth in 10 Claim 1.

5. A composition as claimed in any one of the preceding claims wherein Ar represents:R wherein 11 is 0 or an integer from 1 to 3, R} 15 represents C3-C4 alkyl and R2 1 represents c l -c 4 alkyl or chlorine provided that R2 1 is the same as Rj when n is 2 or 3.

6. A composition as claimed in Claim 5 wherein n^ is 0. 20

7. A composition as claimed in Claim 5 wherein n is 1, 2 or 3 and R2' represents C1-C4 alkyl.

8. A composition as claimed in Claim 7 wherein Rj and R2* both represent methyl.

9. A composition as claimed in Claim 7 or Claim 8 25 wherein n is 1 and the phenyl group is substituted in the 2,3; 2,4; or 2,5 positions. 5 4 3 5 0

10. A composition as claimed in any one of Claims 5 to 9 in which the compound of Formula I is a tropyl benzoate derivative.

11. A composition as claimed in Claim 10 wherein the 05 tropyl benzoate is tropyl-2-methylbenzoate.

12. A composition as claimed in Claim 10 wherein the tropyl benzoate is tropyl 2,4-dimethylbenzoate.

13. A composition as claimed in Claim 10 wherein the tropyl benzoate is tropyl 2,5-dimethylbenzoate. 10

14. A composition as claimed in any one of Claims 5 to 9 in which the compound of Formula I is a pseudotropyl benzoate derivative.

15. A composition as claimed in any one of Claims 1 to 4 wherein the compound of Formula I is a tropyl 15 benzoate in which Ar represents :R. wherein Ηχ and R3 1 independently represent Cx~C 4 alkyl groups.

16. A composition as claimed in Claim 15 wherein the 20 tropyl benzoate is tropyl-3,4-dimethylbenzoate.

17. A composition as claimed in any one of Claims 1 to 4 in which the· compound of Formula 1 is pseudotropyl benzoate· in which Ar represents: 54350 wherein R^ represents alkyl, and Rg' and R^.' independently represent hydrogen or C1-C4 alkyl. 5

18. A composition as claimed in Claim 17 wherein R| represents methyl, and Rg' and R4' independently represent hydrogen or methyl.

19. A composition as claimed in Claim 17 or Claim 18 wherein R4' represents hydrogen. 10

20. A composition as claimed in Claim 17 wherein the pseudotropyl benzoate is pseudotropyl 3,5-dimethyl benzoate.

21. A tropyl or pseudotropyl benzoate derivative of the following general Formula I:15 H,,C - CH —— CH„ II I NCH_ CH 1 I 3 I HgC - CH -CH 2 OgC-Ar 3 4 3 5 Ο wherein:Ar' represents R or R '3 n_ represents 0 or an integer from 1 to 3 Rl represents C1-C4 alkyl provided that for tropyl derivatives Ri is not methyl when n is 0; R2 represents C1-C4 alkyl, C1-C4 alkoxy or halogen, provided that R2 is the same as Ri when n is 2 or 3; and R3 and R4 independently represent hydrogen, C1-C4 alkyl, C1-C4 alkoxy, or halogen, provided that for tropyl derivatives R3 is alkyl and R4 is hydrogen 5 or a pharmaceutically acceptable salt thereof.

22. A compound as claimed in Claim 21 wherein Ri represents methyl, R2 represents methyl, methoxy or chlorine, and R3 and R4 independently represent hydrogen, methyl, methoxy or chlorine, subject to the provisos set forth in Claim 1, or a pharmaceutically acceptable salt thereof .

23. A compound as claimed in Claim 21 or Claim 22 wherein Ar' represents :1, s 4 3 5 Ο wherein ri is 0 or an integer from 1 to 3, Ri represents CJ-C4 alkyl and R2 1 represents C1-C4 alkyl or chlorine, provided that Rj is not methyl when n is 0 and that R2* is the same as Ri 05 when n_ is 2 or 3, or a pharmaceutically acceptable salt thereof .

24. A compound as claimed in Claim 23 wherein ιχ is 0, or a pharmaceutically acceptable salt thereof.

25. A compound as claimed in Claim 23 wherein in is 1, 10 2, or 3 and R2 1 represents Cj-C4 alkyl, or a pharmaceutically acceptable salt thereof.

26. A compound as claimed in Claim 25 wherein R; and R2 1 both represent methyl, or a pharmaceutically acceptable salt thereof . 15

27. A compound as claimed in Claim 25 or Claim 26 wherein n is 1 and the phenyl group is substituted in the 2,3; 2,4; or 2,5 positions, or a pharmaceutically acceptable salt thereof .

28. A compound as claimed in any one of Claims 23 to 20. 27 which is a tropyl benzoate derivative, or a pharmaceutically acceptable salt thereof.

29. A compound as claimed in Claim 28 which is tropyl 2.4- dimethylbenzoate, or a pharmaceutically acceptable salt thereof. 21. 25

30. A compound as claimed in Claim 28 which is tropyl 2.5- dimethylbenzoate, or a pharmaceutically acceptable salt thereof. »> 4 J υ υ

31. A compound as claimed in any one of Claims 23 to 27 which is a pseudotropyl benzoate derivative, or a pharmaceutically acceptable salt thereof.

32. A compound as claimed in Claim 21 or Claim 22 05 which is a tropyl benzoate derivative of Formula I in which Ar' represents:- R^ R. '3 wherein and Rg' independently represent C l -C 4 alkyl groups, 10 or a pharmaceutically acceptable salt thereof.

33. A compound as claimed in Claim 32 which is tropyl-3,4-dimethylbenzoate, or a pharmaceutically acceptable salt thereof.

34. A compound as claimed in Claim 21 or Claim 22 15 which is a pseudotropyl benzoate of Formula I in which Ar' represents:- wherein R 4 represents C 4 -C 4 alkyl, and R3' and R 4 ' independently represent hydrogen or C 4 -C 4 20 alkyl, or a pharmaceutically acceptable salt thereof. 5 4 3 5 0

35. A compound as claimed in Claim 34 wherein Rg represents methyl, and R3' and R 4 ' independently represent hydrogen or methyl, or a pharmaceutically acceptable salt thereof. 05

36. A compound as claimed in Claim 34 or Claim 35 wherein R 4 ' represents hydrogen, or a pharmaceutically acceptable salt thereof.

37. A compound as claimed in Claim 34 which is pseudotropyl 3,5-dimethyl benzoate, or a 10 pharmaceutically acceptable salt thereof.

38. A process for preparing a tropyl or pseudotropyl benzoate as claimed in Claim 21 which comprises the reaction in manner known per se of tropine or pseudotropine and the corresponding acid halide of the 15 following general Formula IV:XOC - Ar' Formula IV wherein Ar' is as defined in Claim 21 and X represents halogen .

39. A process as claimed in Claim 38 wherein a 20 hydrohalide salt of tropine is heated with the acid halide in the absence of a solvent.

40. A process as claimed in Claim 38 wherein pseudotropine is stirred with the acid halide in an aprotic solvent at ambient temperature. ΰ 13 3 0

41. A tropyl or pseudotropyl benzoate derivative of the following general Formula I:CH -CH„ h 2 c· SCH, H 2 C CH I CH„ 0 2 C-Ar wherein:Ar'represents -u or (R 2>n n represents 0 or an integer from 1 to 3 R 1 represents C1-C4 alkyl provided that for tropyl derivatives R^ is not methyl when n 10 is 0; R 2 represents C^-C^ alkyl, C^^-C^ alkoxy or halogen provided that R, is the same as R x when n is 2 or 3; and Rg and R^ independently represent hydrogen, 15 C i -C 4 a -*-kyl, C^-C^ alkoxy, or halogen provided that for tropyl derivatives R 3 is alkyl and R^ is hydrogen; or a pharmaceutically acceptable salt thereof, for use in the treatment of migraine. 5 4 3 5 Ο

42. Λ compound as claimed in any one of Claims 21 to 37 or a pharmaceutically acceptable salt thereof for use in the treatment of migraine.

43. Tropyl 2,4-dimethylbenzoate, or a 05 pharmaceutically acceptable salt thereof, for use in the treatment of migraine.

44. Tropyl 2,5-dimethylbenzoate, or a pharmaceutically acceptable salt thereof, for use in the treatment of migraine. 10

45. Tropyl-3,4-dimethylbenzoate, or a pharmaceutically acceptable salt thereof, for use in the treatment of migraine.

46. Pseudotropyl 3,5-dimethyl benzoate, or a pharmaceutically acceptable salt thereof, for use in 15 the treatment of migraine.

47. A process as claimed in Claim 38 substantially as hereinbefore described.

48. A compound as claimed in Claim 21 whenever prepared by a method as claimed in any one of Claims 20 38, 39, 40 and 47.

49. A pharmaceutical composition according to Claim 1, substantially as hereinbefore described with particular reference to Examples 3-6 of the accompanying Examples.

50. A tropyl or pseudotropyl benzoate derivative of the 25 general Formula I given and defined in claim 21, substantially as hereinbefore described and exemplified.